Researchers from the HUN-REN Szeged Biological Research Centre and HCEMM have just published a new study suggesting that it’s not simply the number of tumor mutations that matters for immunotherapy, but the kind of mutation patterns they create. The team found a distinct “fingerprint” linked to DNA repair problems and chemical exposures that can leave tumors surprisingly hard for the immune system to spot, even when mutation counts are high. The study also points out that a patient’s genetics, including common HLA types in Europeans, can shift how visible the same tumor looks to T cells. The paper was published recently in Molecular Systems Biology.
This article was originally published on MedicalXpress.com
